Intellia Therapeutics (NTLA) Non Operating Investment Income (2019 - 2026)

Intellia Therapeutics (NTLA) has 7 years of Non Operating Investment Income data on file, last reported at -$1.3 million in Q1 2026.

• On a quarterly basis, Non Operating Investment Income fell 381.42% year-over-year to -$1.3 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 56.94% decrease from a year earlier, with the FY2024 full-year figure at $731000.0, changed N/A from the prior year.
• Non Operating Investment Income for Q1 2026 stood at -$1.3 million, down from -$385000.0 in the prior quarter.
• Over the last five years, Non Operating Investment Income for NTLA reached as high as $30.2 million in Q4 2024 and fell as low as -$20.4 million in Q2 2024.
• Historically, Non Operating Investment Income has averaged $331076.9 across 4 years, with a median of -$385000.0 in 2025.
• On a YoY basis, Non Operating Investment Income climbed as much as 715.53% in 2022 and fell as far as 93100.0% in 2022.
• Year by year, Non Operating Investment Income stood at $5.1 million in 2022, then soared by 496.05% to $30.2 million in 2024, then plunged by 101.27% to -$385000.0 in 2025, then tumbled by 230.39% to -$1.3 million in 2026.
• Per Business Quant data, the three most recent Non Operating Investment Income figures were -$1.3 million in Q1 2026, -$385000.0 in Q4 2025, and $3.4 million in Q3 2025.